Combined with voriconazole — Competitive Intelligence Brief

Combined with voriconazole (Combined with voriconazole) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifungal. Area: Infectious Diseases.

phase 2 Antifungal Enzyme Infectious Diseases Small molecule

Target snapshot

Combined with voriconazole (Combined with voriconazole) — LI YAN. This drug works by inhibiting the activity of a specific enzyme.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Combined with voriconazole TARGET	Combined with voriconazole	LI YAN	phase 2	Antifungal	Enzyme
Talazoparib with enzalutamide	talazoparib-with-enzalutamide	Pfizer	marketed	PARP inhibitor and androgen receptor inhibitor	PARP enzymes and androgen receptor	Not yet launched
Test formulation (Treatment A)	test-formulation-treatment-a	Pfizer	marketed	Enzyme inhibitor	Specific enzyme	Not yet determined
Kisqali	ribociclib	Novartis	marketed	CDK4/6 inhibitor; aromatase inhibitor	Cyclin-dependent kinase (CDK) 4 and 6; aromatase enzyme	2017-01-01
PITAVASTATIN MAGNESIUM	PITAVASTATIN MAGNESIUM		marketed	HMG-CoA Reductase Inhibitor [EPC]	3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase	2017-01-01
Xeljanz	Tofacitinib Citrate	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01
Xeljanz	Tofacitinib Citrate	Pfizer	marketed	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifungal class)

1. Cidara Therapeutics Inc. · 1 drug in this class
2. Drugs for Neglected Diseases · 1 drug in this class
3. Fernanda P Silveira, MD, MS · 1 drug in this class
4. LI YAN · 1 drug in this class
5. Novartis · 1 drug in this class
6. Polichem S.A. · 1 drug in this class